**Question:** Drug used in unstable angina & NSTMI -

A. Amiodarone
B. Metoprolol
C. Nitroglycerin
D. Enoxaparin

**Core Concept:** Unstable angina (UA) and Non-ST-elevation myocardial infarction (NSTEMI) are clinical syndromes characterized by acute coronary artery occlusion and subsequent myocardial ischemia, without ST-segment elevation on ECG. These conditions require aggressive medical management to prevent complications and improve outcomes.

**Why the Correct Answer is Right:**

**D. Enoxaparin:** Enoxaparin is a low molecular weight heparin (LMWH) used to prevent and treat venous thromboembolism (VTE) and to reduce mortality in patients with unstable angina and NSTEMI. It is a potent anticoagulant, acting through inhibition of factor Xa, which prevents clot formation and dissolves pre-existing clots. Enoxaparin can be administered subcutaneously, allowing for easy and convenient administration, while reducing the risk of bleeding complications compared to unfractionated heparin.

**Why Each Wrong Option is Incorrect:**

**A. Amiodarone:** Amiodarone is an antiarrhythmic drug mainly used for the treatment of life-threatening arrhythmias, such as ventricular tachycardia and fibrillation. It is not indicated for the management of UA/NSTEMI due to its potential side effects, including bleeding, liver damage, and thyroid dysfunction.

**B. Metoprolol:** Metoprolol is a beta-blocker, used to reduce heart rate and myocardial contractility in various cardiovascular conditions, including hypertension and angina. It is not the first-line therapy for UA/NSTEMI, as it does not directly address the underlying cause of the condition (coronary artery occlusion) and may exacerbate heart failure or hypotension.

**C. Nitroglycerin:** Nitroglycerin is a vasodilator, used for the relief of angina symptoms by dilating coronary arteries, reducing myocardial oxygen demand and increasing cardiac output. It is not effective in UA/NSTEMI management, as these conditions require anticoagulation and antiplatelet therapy (e.g., LMWH and ASA), not vasodilation.

**Clinical Pearl:** In the management of UA/NSTEMI, a combination of antiplatelet agents (e.g., aspirin, clopidogrel, or prasugrel) and anticoagulants (e.g., LMWH or fondaparinux) is the cornerstone of treatment. Other medications, such as beta-blockers and ACE inhibitors, may be added based on clinical context and patient presentation.

**Correct Answer:** Enoxaparin (Enoxaparin is a low molecular weight heparin, similar to enoxaparin but with different molecular structure. They are equally effective and have similar side effects.)

In the context of UA/NSTEMI, Enoxaparin (or other LMWHs like Heparin) is used for its anticoagulant and